Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.20471/acc.2024.63.s2.4

A Comparison of Prostate Biopsies Performed Before and During the COVID-19 Pandemic

Stjepan Frkanec ; Department of Emergency medicine, University Hospital Centre Zagreb, Zagreb, Croatia
Toni Zekulić ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Hrvoje Saić ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Ilija Jurić ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Luka Penezić ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Tvrtko Hudolin ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Tomislav Kuliš ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croati *
Željko Kaštelan ; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croati

* Dopisni autor.


Puni tekst: engleski pdf 250 Kb

str. 29-33

preuzimanja: 0

citiraj


Sažetak

Prostate cancer is the most common cancer in men in developed countries, and
prostate biopsy is the gold standard for diagnosis. However, the COVID-19 pandemic disrupted medical
examinations, potentially leading to delays in diagnostic investigations, particularly for vulnerable
oncology patients. This study included a total of 2796 patients. Biopsies were performed from 2018 to
2021, with a division into pre-pandemic (2018-2019) and pandemic (2020-2021) periods. To compare
the two period and yearly data, we used the Chi-square test and the Cochran-Armitage trend test, respectively.
During the pandemic period, there was a 26.47% decrease in prostate biopsies compared with
pre-pandemic years. The percentage of patients diagnosed with GS 3+3 adenocarcinomas decreased by
37.93% and by 17.66% for GS ≥3+4 (p=0.0164). The percentage of decrease for systematic biopsy was
37.85%, while the percentage of targeted+systematic biopsy increased by 57.89% (p<0.0001). Although
the Department of Urology of the UHC Zagreb continued to perform prostate biopsies during the
COVID-19 pandemic without interruption, there was a noticeable decrease in the number of biopsies.
However, during the pandemic period, we observed an increased proportion of targeted biopsies and
a subsequent increase in the proportion of higher-grade adenocarcinoma (GS ≥3+4). The long-term
impact of the reduced number of biopsies and prostate cancer diagnoses is yet to be determined, but we
believe that this study could be a good starting point for further investigations on this topic.

Ključne riječi

Prostate cancer; Prostate biopsy; COVID-19; Pandemic

Hrčak ID:

323044

URI

https://hrcak.srce.hr/323044

Datum izdavanja:

30.4.2024.

Podaci na drugim jezicima: hrvatski

Posjeta: 0 *